InstitutionMD Anderson
DepartmentTranslational Molecular Pathology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Turtle CJ, Cowan AJ, Shah N, Perales MA, Cairo MS, Saeed H, Budde LE, Tan A, Lee Z, Kai K, Marcondes MQ, Zalevsky J, Tagliaferri MA, Patel KK. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. Future Oncol. 2021 Sep; 17(27):3549-3560. PMID: 34154392.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    2. Gasparetto C, Lentzsch S, Schiller G, Callander N, Tuchman S, Chen C, White D, Kotb R, Sutherland H, Baljevic M, Bensinger W, Venner C, Bahlis N, Rossi A, Biran N, Sheehan H, Saint-Martin JR, Van Domelen D, Kai K, Shah J, Shacham S, Kauffman M, Lipe B, Sebag M, LeBlanc R. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. EJHaem. 2021 Feb; 2(1):56-65. PMID: 35846104; PMCID: PMC9176052.
    3. Kai K, Iwamoto T, Zhang D, Shen L, Takahashi Y, Rao A, Thompson A, Sen S, Ueno NT. CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. Sci Rep. 2018 06 21; 8(1):9427. PMID: 29930294; PMCID: PMC6013474.
      Citations: 11     Fields:    Translation:HumansCells
    4. Kai K, Dittmar RL, Sen S. Secretory microRNAs as biomarkers of cancer. Semin Cell Dev Biol. 2018 06; 78:22-36. PMID: 29258963.
      Citations: 41     Fields:    Translation:HumansCells
    5. Sasai K, Treekitkarnmongkol W, Kai K, Katayama H, Sen S. Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer. Front Oncol. 2016; 6:247. PMID: 27933271; PMCID: PMC5122578.
      Citations: 16     
    6. Treekitkarnmongkol W, Katayama H, Kai K, Sasai K, Jones JC, Wang J, Shen L, Sahin AA, Gagea M, Ueno NT, Creighton CJ, Sen S. Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis. 2016 Dec; 37(12):1180-1189. PMID: 27624071; PMCID: PMC5137261.
      Citations: 15     Fields:    Translation:HumansAnimals
    7. Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther. 2015 Dec; 14(12):2687-99. PMID: 26443806; PMCID: PMC4674309.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    8. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer. 2015; 6(4):310-8. PMID: 25767600; PMCID: PMC4349870.
      Citations: 8     
    9. Kai M, Kogawa T, Liu DD, Fouad TM, Kai K, Niikura N, Hsu L, Willey JS, Theriault RL, Valero V, Ueno NT. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. Clin Breast Cancer. 2015 Feb; 15(1):37-42. PMID: 25258308.
      Citations: 3     Fields:    Translation:Humans
    10. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Hortobagyi GN, Ueno NT, Bertucci F. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013 Nov 25; 15(6):R112. PMID: 24274653; PMCID: PMC3978878.
      Citations: 27     Fields:    Translation:Humans
    11. Zhang W, Kai K, Ueno NT, Qin L. A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells. Cancer Hallm. 2013 Aug; 1(2-3):59-66. PMID: 25309822; PMCID: PMC4189832.
      Citations: 7     
    12. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. 2013 Jul 23; 109(2):318-24. PMID: 23820253; PMCID: PMC3721387.
      Citations: 40     Fields:    Translation:Humans
    13. Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene. 2014 Jan 23; 33(4):440-8. PMID: 23376849; PMCID: PMC3957346.
      Citations: 5     Fields:    Translation:AnimalsCells
    14. Zhang W, Kai K, Choi DS, Iwamoto T, Nguyen YH, Wong H, Landis MD, Ueno NT, Chang J, Qin L. Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Nov 13; 109(46):18707-12. PMID: 23112172; PMCID: PMC3503214.
      Citations: 82     Fields:    Translation:HumansCells
    15. Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, Miwa M, Okada S, Andreeff M, Saya H. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene. 2012 Jun 07; 31(23):2849-61. PMID: 21986948; PMCID: PMC3271180.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    16. Sampetrean O, Saga I, Nakanishi M, Sugihara E, Fukaya R, Onishi N, Osuka S, Akahata M, Kai K, Sugimoto H, Hirao A, Saya H. Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia. 2011 Sep; 13(9):784-91. PMID: 21969812; PMCID: PMC3182271.
      Citations: 48     Fields:    Translation:AnimalsCells
    17. Arima Y, Hayashi N, Hayashi H, Sasaki M, Kai K, Sugihara E, Abe E, Yoshida A, Mikami S, Nakamura S, Saya H. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer. 2012 Jun 01; 130(11):2568-79. PMID: 21717460.
      Citations: 26     Fields:    Translation:HumansCells
    18. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011 Mar 08; 19(3):387-400. PMID: 21397861.
      Citations: 483     Fields:    Translation:HumansAnimalsCells
    19. Hayashi M, Kai K, Okumura Y, Osako T, Arima N, Iwase H, Nishimura R. Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy. Oncol Lett. 2011 Mar; 2(2):303-308. PMID: 22866081; PMCID: PMC3410577.
      Citations: 2     
    20. Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci. 2010 Mar; 101(3):673-8. PMID: 20028388.
      Citations: 73     Fields:    Translation:Animals
    21. Kai K, Arima Y, Kamiya T, Saya H. Breast cancer stem cells. Breast Cancer. 2010 Apr; 17(2):80-5. PMID: 19806428.
      Citations: 32     Fields:    Translation:HumansCells
    22. Kai K, Nagano O, Sugihara E, Arima Y, Sampetrean O, Ishimoto T, Nakanishi M, Ueno NT, Iwase H, Saya H. Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci. 2009 Dec; 100(12):2275-82. PMID: 19737148.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    23. Kai K, Zhang Z, Yamashita H, Yamamoto Y, Miura Y, Iwase H. Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer. BMC Cancer. 2008 Sep 16; 8:262. PMID: 18796146; PMCID: PMC2564977.
      Citations: 10     Fields:    Translation:HumansCells
    24. Kai K, Arima N, Miyayama H, Yamamoto Y, Iwase H, Nishimura R. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study. Breast Cancer. 2009; 16(1):42-8. PMID: 18504642.
      Citations: 3     Fields:    Translation:Humans
    25. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008 Aug; 110(3):465-75. PMID: 17805961.
      Citations: 67     Fields:    Translation:Humans
    26. Kai K, Nishimura R, Arima N, Miyayama H, Iwase H. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol. 2006 Dec; 11(6):426-33. PMID: 17180510.
      Citations: 14     Fields:    Translation:Humans
    27. Doi K, Beppu T, Ishiko T, Kai K, Maeda K, Nakagawa M, Takahashi M, Egami H, Ogawa M. [Significance of local ablation therapy following portal embolization therapy for hepatocellular carcinoma with portal vein tumor thrombus]. Gan To Kagaku Ryoho. 2003 Oct; 30(11):1702-5. PMID: 14619498.
      Citations:    Fields:    Translation:HumansCells
    28. Takahashi M, Beppu T, Doi K, Ishiko T, Kai K, Doi Y, Okabe H, Egami H, Ashihara H, Fujiyama S, Ogawa M. [Multidisciplinary treatment for hepatocellular carcinoma invading the stomach]. Gan To Kagaku Ryoho. 2003 Oct; 30(11):1741-4. PMID: 14619508.
      Citations: 2     Fields:    Translation:Humans
    29. Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. Journal of Cancer. 6:310-318.
    30. A successfully resected case of adult hepatoblastoma with hepatitis C. Japanese Journal of Gastroenterological Surgery. 39:72-77.
    31. Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases. Molecular Cancer Therapeutics. 14:2687-2699.
    32. Functional significance of Aurora kinases-p53 protein family interactions in cancer. Frontiers in Oncology. 6.
    33. A resected case of primary lymphoma of the liver. Japanese Journal of Gastroenterological Surgery. 38:644-649.
    34. Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy. Oncology Letters. 2:303-308.
    KAI's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (181)
    Co-Authors (16)
    Similar People (60)
    Same Department Expand Description